- Home
- LSF vs AGEN Comparison
LSF vs AGEN Comparison
Compare LSF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | AGEN |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 126.2M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | LSF | AGEN |
|---|---|---|
| Price | $2.31 | $3.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $14.50 |
| AVG Volume (30 Days) | 206.0K | ★ 628.7K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $48,146,862.00 | ★ $106,829,000.00 |
| Revenue This Year | $18.05 | $67.15 |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $1.98 | $1.38 |
| 52 Week High | $8.29 | $7.34 |
Technical Indicators
Market Signals| Indicator | LSF | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 25.02 |
| Support Level | $1.98 | $3.26 |
| Resistance Level | $2.67 | $4.00 |
| Average True Range (ATR) | 0.26 | 0.26 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 31.90 | 7.66 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).